November 26, 2008 - ATS Medical Inc. this week said the first three commercial implants of the ATS 3f Aortic Bioprosthesis were completed Nov. 17 and 18 by Allan Stewart, M.D., director, aortic surgery program at Columbia University Medical Center in New York.
The ATS 3f Aortic Bioprosthesis is the company’s first entry into the $400-plus million U.S. tissue valve market. The ATS 3f is a new generation, stentless pericardial aortic tissue valve that is unlike any other valve.
